Patents issue to Advaxis, Inc. for cancer immunotherapies for solid tumors in humans and dogs
The United States Patent and Trademark Office (USPTO) has approved notices of issuance for two patents covering the composition and methods of use for ADXS-cHER2 (Patent Numbers 11/415,271, 12/213,969 and 13/254607). Advaxis is developing ADXS-cHER2 to target the Her2 receptor, which is overexpressed in certain solid-tumor cancers, including bone cancer (or osteosarcoma), breast cancer, esophageal, and gastric cancer. Advaxis plans to initiate a Phase 1 trial with ADXS-cHER2 in pediatric osteosarcoma, for which it received Orphan Drug Designation, and is pursuing early development clinical collaborations for breast, esophageal and gastric cancers.
Mainly, these patents cover the molecular composition of the ADXS-cHER2 compound, as well as methods of use against tumors that express the protein Her2/neu in humans. It also covers other medical applications for ADXS-cHER2. And importantly for media outlets looking for news stories, these patents also cover the use of ADXS-cHER2 in dogs.
Date: June 30, 2014